Literature DB >> 25017118

Galanin receptor 2 utilizes distinct signaling pathways to suppress cell proliferation and induce apoptosis in HNSCC.

Takeharu Kanazawa1, Kiyoshi Misawa2, Yuki Misawa2, Mikiko Maruta1, Takayuki Uehara3, Kazumi Kawada1, Takafumi Nagatomo1, Keiichi Ichimura1.   

Abstract

Galanin and its receptors, GALR1 and GALR2, are tumor suppressors and represent therapeutic targets in head and neck squamous cell carcinoma (HNSCC). In the present study, it was demonstrated that the re‑expression of GALR1 in GALR1 and GALR2‑negative HNSCC cells suppresses tumor cell proliferation. This is mediated via extracellular‑regulated protein kinase‑1/2 (ERK1/2)‑dependent effects on the cyclin‑dependent kinase inhibitors (CKI) and cyclin D1. In combination with galanin, GALR2 also suppressed proliferation by increasing CKI and decreasing cyclin D1 levels. In contrast to GALR1, overexpression of GALR2 also induced caspase‑3‑dependent apoptosis. It was identified that in GALR2‑transfected cells, galanin induced activation of ERK1/2 and suppressed cell proliferation. Galanin stimulation also decreased the expression of cyclin D1 and induced apoptotic DNA ladder formation in GALR2‑transfected cells. Pretreatment with the ERK1/2‑specific inhibitor U0126 and pertussis toxin prevented the suppression of cyclin D1 expression, however did not affect DNA ladder formation. In conclusion, GALR2 expression in the presence of galanin exerts antitumor effects via cell cycle arrest and apoptotic pathways, and reactivation of these pathways may have therapeutic benefits in HNSCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25017118     DOI: 10.3892/mmr.2014.2362

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  An assembly of galanin-galanin receptor signaling network.

Authors:  Lathika Gopalakrishnan; Oishi Chatterjee; Chinmayi Raj; Deepshika Pullimamidi; Jayshree Advani; Anita Mahadevan; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2020-11-02       Impact factor: 5.782

2.  Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: Potential utility as biomarkers for prognosis.

Authors:  Takeharu Kanazawa; Kiyoshi Misawa; Hirofumi Fukushima; Yuki Misawa; Yukiko Sato; Mikiko Maruta; Shoichiro Imayoshi; Gen Kusaka; Kazuyoshi Kawabata; Hiroyuki Mineta; Thomas E Carey; Hiroshi Nishino
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

3.  Galanin Receptors (GalR1, GalR2, and GalR3) Expression in Colorectal Cancer Tissue and Correlations to the Overall Survival and Poor Prognosis of CRC Patients.

Authors:  Jacek Kiezun; Janusz Godlewski; Bartlomiej E Krazinski; Zygmunt Kozielec; Zbigniew Kmiec
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 4.  The Galaninergic System: A Target for Cancer Treatment.

Authors:  Manuel Lisardo Sánchez; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2022-08-01       Impact factor: 6.575

Review 5.  G-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer?

Authors:  Takeharu Kanazawa; Kiyoshi Misawa; Yuki Misawa; Takayuki Uehara; Hirofumi Fukushima; Gen Kusaka; Mikiko Maruta; Thomas E Carey
Journal:  Toxins (Basel)       Date:  2015-08-05       Impact factor: 4.546

6.  Role of Nrf2 signaling pathway in the radiation tolerance of patients with head and neck squamous cell carcinoma: an in vivo and in vitro study.

Authors:  Tao Wang; Peng Hu; Bo Li; Jun-Peng Zhang; Yu-Feng Cheng; Ye-Min Liang
Journal:  Onco Targets Ther       Date:  2017-03-23       Impact factor: 4.345

7.  Galanin System in Human Glioma and Pituitary Adenoma.

Authors:  Sarah Falkenstetter; Julia Leitner; Susanne M Brunner; Tim N Rieder; Barbara Kofler; Serge Weis
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-24       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.